CDK Inhibitors Patent Landscape 2009France Innovation Scientifique et TransfertOctober 29, 2009 83 Pages - SKU: FIST2496655 |
Alterations in CDK activity have been associated in the development of viral infections, neurodegenerative dis orders such as Alzheimer’s disease and proliferative diseases such as renal diseases and cancers. These observations led the CDK family to become a central target for the development of new therapies. During the last two decades, evolution of patent filings of CDK inhibit ors shows two major phases. A strong increase until 2002 is associated with the capacity of CDK inhibitors to target a large number of diseases. Results of advanced clinical stages confirm the potential of these compounds but emphasize new challenges in order to reach marketable products. A significant decrease follows until 2005 when a new generation of CDK inhibitors takes the lead in R&D interest. This IP Overview provides you with a comprehensive panorama of the intellectual property landscape of this new and promising sector and helps you:
|
Related Markets
- Diseases & Conditions
- Alzheimer's Disease
- Pharmaceuticals
- Drug Discovery
- Therapeutic Area
- Infectious Diseases
- CNS/Neurology
- Oncology/Hematology
Oncology/Hematology Reports
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Peptides
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Angiogenesis and Protein Kinase Inhibitors